Brigitte Velkeniers Brigitte Velkeniers Kris Poppe Kris Poppe Free University of Brussels Free University of Brussels Thyroid & Pregnancy Thyroid & Pregnancy
Brigitte VelkeniersBrigitte Velkeniers
Kris PoppeKris Poppe
Free University of BrusselsFree University of Brussels
Thyroid & PregnancyThyroid & Pregnancy
Classification
• Thyroid function &– Normal reproduction
• dysfunction and menstruations
– Changes during pregnancy
• Thyroid disorders BEFORE pregnancy– In association with
• infertility / COH
• Thyroid disorders DURING pregnancy– Thyroid Autoimmunity –without dysfunction-
– Hypothyroidism / Hyperthyroidism
• Thyroid disorders AFTER pregnancy– Post Partum Thyroiditis / Graves’-Basedow
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Woman (23 years)
She stopped 6 m before the consultation with thiamazol
for a Graves’ disease
She consulted to « talk » about the relationship between
thyroid disorders and pregnancy
Next visit 6 months later
unless pregnancy or relapse of the Graves’ disease
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
Does hyperthyroidism influence fertility ?
• direct effects– T3-receptors are present on
» theca cells
» corpus luteum
» throphoblast
• indirect effects– GnRH secretion
– PRL secretion
– SHBG levels
– Coagulation factors
» In hypoT: decreased levels of factors VII, VIII, IX, and
XI
Poppe K et al. Clinical Endocrinology 2007
46/214 = 22 % 18/124 = 15 %
46/214 = 22 % 18/124 = 15 %
The prevalence of infertility due to these
menstrual irregularities
is however unknown
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
One month before the planned consultation,
the patient came with symptoms of hyperthyroidism,
biologically confirmed
PTU 3*1
was started
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
No symptoms, but
she had a pregnancy wish
PTU 3*1 – LT4 50 ug/d
continued
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
What would you propose in general and
would you modify the treatment ?
PTU Methimazole
Protein Binding 75 % 0
Half-life 75 min 4-6 h
Duration of action 12-24 h > 24 h
Transplacental
passageLower Higher
Breast milk levels Lower Higher
PTU was historically preferred over MMI (especially in the US), with the rationale that the former was more water soluble and more extensively bound to albumin than MMI (limiting the trans-placental passage)
– this seems however to be unlikely …
Krassas et al. Endocrine Review 2010 in press
Side-effects of ATD in pregnancy
‘MMI embryopathy’ includes aplasia cutis and choanal or esophageal atresia
– Aplasia cutis is the absence of skin and accessory structures over the scalp.
Skin defects are estimated to occur in 1 out of ~4,000 to ~10,000 pregnancies and, from the scarce data available, it is considered that this incidence is not above background in pregnant women who have received MMI.
– Choanal or esophageal atresia is a severe congenital anomaly requiring
major surgery to repair and is considered to have a higher incidence than expected in fetuses exposed to MMI in the first trimester. The relative risk of choanal atresia in pregnant women receiving MMI was estimated to be ~17-fold greater than in the general population, although it should be noted that such congenital birth defects could also be attributed to thyrotoxicosis per se rather than to the administration of MMI.
Krassas et al. Endocrine Review 2010 in press
Aplasia cutis
- Available evidence suggests that MMI may be associated with congenital
anomalies, PTU should be used as a first line drug especially during 1st
trimester’s organogenesis.
- MMI may be prescribed if PTU is not available, or in case of intolerance
- T4 is not recommended with ATD during pregnancy
Graves’ treatment
Mortimer RH, et al. 1997 Methimazole and propylthiouracil equally cross the perfused
human term placental lobule. JCEM 82:3099-3102
Bournaud C, Orgiazzi J 2003 Antithyroid agents and embryopathies. Ann Endo (Paris) 64:366-369
• With regard to PTU, a controversy has recently come to light following the
alarming report that the use of PTU for treatment of pediatric GD was
associated with a significant risk of liver failure
– the Endocrine Society recommended that PTU stopped being used in the
pediatric population.
In the context of the first trimester of pregnancy, however, PTU remains the
drug of choice with a switch to MMI treatment thereafter. Finally, pregnant
women under PTU should monitor their liver function tests regularly.
- Rivkees SA, Mattison DR 2009 Ending propylthiouracil-induced liver failure in children.
NEJM 360:1574-1575
- FDA Statement (Medwatch Online) 2009 Information for healthcare
professionals PTU induced liver failure.
- The Endocrine Society Statement on the NEJM Letter to the Editor on PTU use in children (2009)
Side-effects of ATD in pregnancy
• Surgery
– may be necessary in women who cannot tolerate thionamides
because of allergy or agranulocytosis or have a huge goiter
• It is however associated with an increased risk of spontaneous
abortion or premature delivery. These risks are minimized by
operating during the second trimester.
Mother Placental barrierPlacental barrier FetusFetus
AntiAnti--TSH receptorTSH receptor
antibodies antibodies
with stimulating and/orwith stimulating and/or
blocking activityblocking activity
ThionamideThionamide
antithyroid drugsantithyroid drugs
(PTU, MMI )(PTU, MMI )
Hyperthyroidism ?Hyperthyroidism ?
Hypothyroidism ?Hypothyroidism ?
TSH-Rec Abs freely cross the placenta and can stimulate the fetal thyroid.
These antibodies should be measured before pregnancy or by the
end of the 2nd trimester in mothers with current GD, or with a history
of GD and treatment with I-131 or thyroidectomy, or with a previous
neonate with GD.
Women who have negative TRAb and do not require ATD have a
very low risk of fetal or neonatal thyroid dysfunction.
131-I should not be given to a woman who is pregnant.
If inadvertently treated, the patient should be promptly informed of
the radiation danger to the fetus, including thyroid destruction if treated
after the 12th week of gestation.
no pregnancy < 6 months after I*
MATERNAL HYPERTHYROIDISM
FETAL ASPECTS
Kamijo K 2007
TSH-receptor antibodies determined by the first, second and third generation assay and thyroid stimulating
antibody in pregnant patients with Graves’ disease. Endocr J 54:619–624
In women with elevated TRAb or in women treated with ATD, fetal ultrasound should
be performed to look for evidence of fetal thyroid dysfunction
- lgrowth restriction, hydrops, presence of goiter or cardiac failure.
Umbilical blood sampling should be considered only if the diagnosis of fetal thyroid
disease is not reasonably certain from the clinical data and if the information gained
would change the treatment.
All newborns of mothers with GD should be evaluated by the medical care
provider for thyroid dysfunction and treated if necessary.
MATERNAL HYPERTHYROIDISM:
FETAL ASPECTS
Eisenstein Z et al. Intellectual capacity of subjects exposed to
methimazole or propylthiouracil in utero. Eur J Ped 1992 151:558-9.
Krassas et al. Endocrine Review 2010 in press
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
We advised :
To STOP LT4
To continue PTU 2*1
To continue her contraception
until thyroid function was normalized
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
No symptoms
PTU 2*1
Miscarriage at the end of 2003
(contraception ??)
Next visit in 2 months
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
Is Graves-Basedow associated with
an adverse pregnancy outcome ?
Prevalence
• The prevalence of hyperthyroidism has been estimated
to range between 0.1% and 1%
• 0.4% clinical and 0.6% subclinical
– The most common cause is GD (85% of overt hyperthyroidism in pregnant women).
– A second common aetiology is gestational transient
thyrotoxicosis (GTT) or non-autoimmune hyperthyroidism.
• differentiation of GD from GTT is supported by presence of evidence of autoimmunity and/or a goiter
Krassas et al. Endocrine Review 2010 in press
GD – pregnancy morbidity and mortality
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
No symptoms
PTU 2*1
8 weeks pregnant !
Q
What would you do now ?
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Treatment was stopped
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Normal pregnancy
No treatment
Next visit 6 weeks after pregnancy
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
6w PP
Symptomatic hyperthyroidism
- 2*1 thiamazol
- Propanolol
- Next visit 2 weeks later
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
DD ?
DD GD – PPT
Stagnaro-Green A. Postpartum thyroiditis.
JCEM. 2002 Sep;87(9):4042-7.
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
2-3 months PP
TSI –
Scintigraphy: no uptake
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
Is PPT frequent ?
PPT
– Prevalence between 3-17%
• 50 % in women with TPO-Ab
• 25 % in women with DM-1
– Recurrence in subsequent pregnancies (70%)
• The pathologic findings in the two disorders are similar and both are
associated with particular HLA-B and HLA-D haplotypes, suggesting
that inherited risk factors are important.
Stagnaro-Green A. Postpartum thyroiditis.
JCEM. 2002 Sep;87(9):4042-7.
Stagnaro-Green A. Postpartum thyroiditis.
JCEM. 2002 Sep;87(9):4042-7.
20-40%
20-30%
40-50%
20-30%
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
How would you treat ?
Transient thyrotoxicosis No therapy or beta-blockers
Transient
hypothyroidism
T4 for 12-18 months; then discontinue
& check TSH
Permanent
hypothyroidismIndefinite T4 replacement
Treatment of PPT
Stagnaro-Green, Best Practice in Clinical Endocrinology 2004
PREVENTION of PPT ?
– Selenium supplementation may decrease inflammatory activity in pregnant
women with AITD and may reduce the risk of PPT in women who are
positive for TPO-abs.
• This was illustrated in a trial of 151 TPO-positive women randomly assigned to
receive selenium (200 mcg daily) or placebo (beginning at about the 12th week of
gestation). PPT occurred in 22 of 77 women (29 percent) in the selenium group,
compared to 36 of 74 (49 percent) in the placebo group.
– The routine clinical application of this supplementation requires further study.
Negro R et al. The influence of selenium supplementation on postpartum thyroid status in
pregnant women with thyroid peroxidase autoantibodies. JCEM 2007 Apr;92(4):1263-8.
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
- Methimazol STOPPED
- Propanolol not supported
- Diltiazem started
-Next visit 1 month later
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
4-10 months PP
TSI –
LT4 25 ug/d
- PP depression
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Q
PPT & PP depression ?
PPT - PD
Lucas A et al. Postpartum thyroid dysfunction and postpartum depression:
are they two linked disorders? Clin Endo (Oxf). 2001 Dec;55(6):809-14.
PPT - PD
PPT - PD
• The general PD incidence rate of 1,7 % was not higher
in women with hormone abnormalities caused by PPTD.
– Women with a past history of depression present a higher risk of
PD while those who breast fed did not have an increased risk.
Stagnaro-Green, Best Practice in Clinical Endocrinology 2004
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
4-10 months PP
TSI –
LT4 25 ug/d
- PP depression (SSRI)
- next visit in 6 months
unless pregnant
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Routine control
No symptoms
Treatment: LT4 25 ug/d
next visit in 6 months,
unless pregnant
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Symptomatic
Hyperthyroidism
…
Q
What would
you propose ?
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
All posibilities were
proposed and the
patient wanted
a « definitive »
treatment with I*
…
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
After I*, increase in TSH
New pregnancy wanted
(6m after I*)
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
75 ug LT4 started to keep
serum TSH < 2.5 mIU/L
Abalovich M et al. J Clin Endocrinol Metab. 2007 Aug
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
> 6 months later,
still not pregnant
with an optimal TSH …
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Idiopathic infertility
Q
Is this associated with
a higher prevalence of AITD ?
Poppe K et al. Nat Clin Pract Endocrinol Metab. 2008
Cause of
infertilityn (%) Age# TSH° FT4° TPO-Abs^
Female 197 (45) 34 6 1.3 (0.9) * 12 (2) 18 % *
Male 168 (38) 31 5 * 1.3 (0.9) * 12 (2) 11 %
Idiopathic 73 (17) 32 5 1.2 (1.1) * 12 (2) 7 %
All 438 (100) 32 5 1.3 (0.9) * 12 (2) 14 %
Controls 100 33 4 1.1 (0.8) 11 (2) 8 %
# mean SD ° median (interquartile) ^ % positive
* p < 0.05 against controls
Poppe et al. Thyroid 2002
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Idiopathic infertility
COH started and ICSI planned
Q
What do you expect,
concerning
the TSH evolution ?
(R= 0.5; p < 0.0001)
Muller et al. JCEM 2000
------- before ART _______ after ART
p < 0.0001 p < 0.0001
Conclusion
• Serum TSH significantly increased and FT4
decreased after COH
• Remaining Q
– TAI status in relation to TSH, FT4 after COH ?
– Only one time point that TSH and FT4 was measured
– Outcome of ART ?
1
TSH
0.0
2.0
4.0
6.0
8.0
0 20 40 60 80 100
Time (days)
mU
/ L
FT4
10.0
11.0
12.0
13.0
14.0
15.0
16.0
0 20 40 60 80 100
Time (days)
ng
/ L
FT4
TSH TSH
TPO +
TPO -
TPO -
TPO +
Serum TSH and FT4 according to TAI status
p< 0.001
p=0.005
Poppe et al. JCEM 2004
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Idiopathic infertility
COH started and ICSI planned
LT4 increased to 125 ug/d
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
Pregnant !
LT4 increased to 125 ug/d
1
1513 13
97
3 3 2 1 1 1 14
6
40
36
15
2 2 1 10.01
1.01
2.01
3.01
4.01
5.01
Aug
-02
Jan-03
Mar-0
3
May
-03
Jul-0
3
Oct-0
3
Jan-04
Apr-0
4
May
-04
Jul-0
4
Jan-05
Jan-05
Feb
-05
Feb
-05
Mar-0
5
Apr-0
5
Jun-05
Jul-0
5
Oct-0
5
Apr-0
6
Aug
-06
Sep
-06
Nov-06
Jan-07
May
-07
Jul-0
7
Dec-07
Feb
-08
Aug
-08
Oct-0
8
Jan-09
May
-09
Sep
-09
Seru
m F
T4 &
TS
I
0
10
20
30
40
50
60
70
80
Seru
m T
SH
TSH (mIU/l)
FT4 (ng/l)
TSI (U/L)
6 months PP
LT4 kept at 125 ug/d, without problems